Department of Physiology, College of Basic Medical Sciences, Jilin University, No. 126, Xinmin Street, Changchun, 130021, Jilin Province, People's Republic of China.
Department of Anesthesiology, The Third Hospital of Jilin University, Changchun, 130033, People's Republic of China.
Cardiovasc Drugs Ther. 2022 Aug;36(4):575-588. doi: 10.1007/s10557-021-07154-6. Epub 2021 Apr 15.
C/EBP homologous protein (CHOP) has been identified as a suitable therapeutic target to combat atherosclerosis but the mechanism has not been fully studied. Here, we sought to define the role and underlying mechanism of CHOP in atherosclerosis.
Mouse models of atherosclerosis in ApoE mice were established by high-fat feeding, where miR-208 expression was determined. Then atherosclerotic plaque tissues were isolated from the model mice. Loss- and gain-function assays were performed on trypsinized vascular smooth muscle cells (VSMCs) to test the in vitro effect of CHOP in controlling the tribbles homologue 3 (TRIB3)/microRNA-208 (miR-208)/tissue inhibitor of metalloproteinases-3 (TIMP3) axis in atherosclerosis by determining cell proliferation and migration as well as blood lipid levels. Moreover, expression of α-smooth muscle actin (α-SMA) and type I collagen expression was determined using immunofluorescence staining to assess plaque stability in mice.
miR-208 expression was elevated in atherosclerosis samples and miR-208 overexpression promoted proliferation and migration of VSMCs but diminished plaque stability in mice. TIMP3 was targeted by miR-208, which could be abrogated by upregulation of TIMP3. In addition, CHOP increased TRIB3 expression to upregulate miR-208 and to downregulate TIMP3, which potentiated VSMC proliferation and migration in vitro and in vivo.
Taken together, inhibition of CHOP may inhibit the proliferation and migration of VSMCs as well as reduce the levels of TC, TG, and LDL-C but increase the level of HDL-C through the TRIB3/miR-208/TIMP3 axis, thereby inhibiting the progression of atherosclerosis.
C/EBP 同源蛋白(CHOP)已被确定为对抗动脉粥样硬化的合适治疗靶点,但该机制尚未完全研究。在这里,我们试图确定 CHOP 在动脉粥样硬化中的作用和潜在机制。
通过高脂喂养建立 ApoE 小鼠动脉粥样硬化模型,测定 miR-208 的表达。然后从模型小鼠中分离动脉粥样硬化斑块组织。在分离的血管平滑肌细胞(VSMCs)中进行 CHOP 的缺失和获得功能实验,通过测定细胞增殖和迁移以及血脂水平,来检测 CHOP 控制 Tribbles 同源物 3(TRIB3)/微小 RNA-208(miR-208)/基质金属蛋白酶抑制剂 3(TIMP3)轴在动脉粥样硬化中的体外作用。此外,通过免疫荧光染色来确定斑块稳定性α-平滑肌肌动蛋白(α-SMA)和 I 型胶原的表达。
miR-208 在动脉粥样硬化样本中的表达升高,miR-208 过表达促进了 VSMCs 的增殖和迁移,但降低了小鼠的斑块稳定性。miR-208 靶向 TIMP3,上调 TIMP3 可阻断 miR-208 的作用。此外,CHOP 增加了 TRIB3 的表达,从而上调了 miR-208,下调了 TIMP3,增强了 VSMCs 的增殖和迁移。
综上所述,抑制 CHOP 可能通过 TRIB3/miR-208/TIMP3 轴抑制 VSMCs 的增殖和迁移,降低 TC、TG 和 LDL-C 的水平,同时提高 HDL-C 的水平,从而抑制动脉粥样硬化的进展。